{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:14Z","timestamp":1790678594263,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2003,6,20]],"date-time":"2003-06-20T00:00:00Z","timestamp":1056067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,6,20]],"date-time":"2003-06-20T00:00:00Z","timestamp":1056067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,7,1]]},"DOI":"10.1038\/sj.leu.2402988","type":"journal-article","created":{"date-parts":[[2003,6,30]],"date-time":"2003-06-30T15:31:11Z","timestamp":1056987071000},"page":"1301-1312","source":"Crossref","is-referenced-by-count":125,"title":["WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies"],"prefix":"10.1038","volume":"17","author":[{"given":"C","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Cheever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gaiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,6,20]]},"reference":[{"key":"BF2402988_CR1","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.leu.2401544","volume":"13","author":"M Baudard","year":"1999","unstructured":"Baudard M, Beauchamp-Nicoud A, Delmer A, Rio B, Blanc C, Zittoun R et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 1999; 13: 1481\u20131490.","journal-title":"Leukemia"},{"key":"BF2402988_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","volume":"351","author":"AK Burnett","year":"1998","unstructured":"Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700\u2013708.","journal-title":"Lancet"},{"key":"BF2402988_CR3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199905273402107","volume":"340","author":"ML Heaney","year":"1999","unstructured":"Heaney ML, Golde DW . Myelodysplasia. N Engl J Med 1999; 340: 1649\u20131660.","journal-title":"N Engl J Med"},{"key":"BF2402988_CR4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199808273390907","volume":"339","author":"CH Pui","year":"1998","unstructured":"Pui CH, Evans WE . Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605\u2013615.","journal-title":"N Engl J Med"},{"key":"BF2402988_CR5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RH Collins Jr","year":"1997","unstructured":"Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433\u2013444.","journal-title":"J Clin Oncol"},{"key":"BF2402988_CR6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","volume":"100","author":"C Guglielmi","year":"2002","unstructured":"Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397\u2013405.","journal-title":"Blood"},{"key":"BF2402988_CR7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.V94.4.1201","volume":"94","author":"JH Falkenburg","year":"1999","unstructured":"Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201\u20131208.","journal-title":"Blood"},{"key":"BF2402988_CR8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1001\/archinte.1983.00350090104017","volume":"143","author":"KA Foon","year":"1983","unstructured":"Foon KA, Smalley RV, Riggs CW, Gale RP . The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 1983; 143: 1726\u20131731.","journal-title":"Arch Intern Med"},{"key":"BF2402988_CR9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s001090050195","volume":"76","author":"RJ Arceci","year":"1998","unstructured":"Arceci RJ . The potential for antitumor vaccination in acute myelogenous leukemia. J Mol Med 1998; 76: 80\u201393.","journal-title":"J Mol Med"},{"key":"BF2402988_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/modpathol.3880035","volume":"13","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193\u2013207.","journal-title":"Mod Pathol"},{"key":"BF2402988_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0378-1119(01)00593-5","volume":"273","author":"V Scharnhorst","year":"2001","unstructured":"Scharnhorst V, van der Eb AJ, Jochemsen AG . WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141\u2013161.","journal-title":"Gene"},{"key":"BF2402988_CR12","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.94.15.8132","volume":"94","author":"GB Silberstein","year":"1997","unstructured":"Silberstein GB, Van Horn K, Strickland P, Roberts Jr CT, Daniel CW . Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997; 94: 8132\u20138137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402988_CR13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-A","volume":"60","author":"KM Call","year":"1990","unstructured":"Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509\u2013520.","journal-title":"Cell"},{"key":"BF2402988_CR14","first-page":"405","volume":"6","author":"H Miwa","year":"1992","unstructured":"Miwa H, Beran M, Saunders GF . Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405\u2013940.","journal-title":"Leukemia"},{"key":"BF2402988_CR15","first-page":"970","volume":"7","author":"T Miyagi","year":"1993","unstructured":"Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I . Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970\u2013977.","journal-title":"Leukemia"},{"key":"BF2402988_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2739\/kurumemedj.48.129","volume":"48","author":"S Fukahori","year":"2001","unstructured":"Fukahori S . Quantification of WT1 mRNA by competitive NASBA in AML patients. Kurume Med J 2001; 48: 129\u2013134.","journal-title":"Kurume Med J"},{"key":"BF2402988_CR17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.2001.02912.x","volume":"114","author":"K Kreuzer","year":"2001","unstructured":"Kreuzer K, Saborowski A, Lupberger J, Appelt C, Na I, Coutre P et al. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human disease. Br J Haematol 2001; 114: 313\u2013318.","journal-title":"Br J Haematol"},{"key":"BF2402988_CR18","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","volume":"84","author":"K Inoue","year":"1994","unstructured":"Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071\u20133079.","journal-title":"Blood"},{"key":"BF2402988_CR19","first-page":"1127","volume":"10","author":"P Patmasiriwat","year":"1996","unstructured":"Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF . Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia 1996; 10: 1127\u20131133.","journal-title":"Leukemia"},{"key":"BF2402988_CR20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.leu.2400620","volume":"11","author":"D Schmid","year":"1997","unstructured":"Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia. 1997; 11: 639\u2013643.","journal-title":"Leukemia"},{"key":"BF2402988_CR21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.leu.2402434","volume":"16","author":"T Karakas","year":"2002","unstructured":"Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002; 16: 846\u2013854.","journal-title":"Leukemia"},{"key":"BF2402988_CR22","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood.V90.3.1217","volume":"90","author":"L Bergmann","year":"1997","unstructured":"Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217\u20131225.","journal-title":"Blood"},{"key":"BF2402988_CR23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2400521","volume":"11","author":"E Algar","year":"1997","unstructured":"Algar E, Blackburn D, Kromykh T, Taylor G, Smith P . Mutation analysis of the WT1 gene in sporadic childhood leukaemia. Leukemia 1997; 11: 110\u2013113.","journal-title":"Leukemia"},{"key":"BF2402988_CR24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000040973","volume":"102","author":"E Niegemann","year":"1999","unstructured":"Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebener U . wt1 gene expression in childhood leukemias. Acta Haematol 1999; 102: 72\u201376.","journal-title":"Acta Haematol"},{"key":"BF2402988_CR25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000041057","volume":"103","author":"U Ozgen","year":"2000","unstructured":"Ozgen U, Anak S, Ozbek U, Sarper N, Eryilmaz E, Agaoglu L et al. wt1 gene expression in childhood acute leukemias. Acta Haematol 2000; 103: 229\u2013302.","journal-title":"Acta Haematol"},{"key":"BF2402988_CR26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/sj.leu.2402512","volume":"16","author":"J Trka","year":"2002","unstructured":"Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16: 1381\u20131389.","journal-title":"Leukemia"},{"key":"BF2402988_CR27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0609.1999.tb01121.x","volume":"63","author":"A Gaiger","year":"1999","unstructured":"Gaiger A, Linnerth B, Mann G, Schmid D, Heinze G, Tisljar K et al. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur J Haematol 1999; 63:86\u201393.","journal-title":"Eur J Haematol"},{"key":"BF2402988_CR28","first-page":"1060","volume":"9","author":"HD Menssen","year":"1995","unstructured":"Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060\u20131067.","journal-title":"Leukemia"},{"key":"BF2402988_CR29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0609.1997.tb01681.x","volume":"58","author":"M Carapeti","year":"1997","unstructured":"Carapeti M, Goldman JM, Cross NC . Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia. Eur J Haematol 1997; 58: 346\u2013349.","journal-title":"Eur J Haematol"},{"key":"BF2402988_CR30","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/sj.leu.2402675","volume":"16","author":"D Cilloni","year":"2002","unstructured":"Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115\u20132121.","journal-title":"Leukemia"},{"key":"BF2402988_CR31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/088800199277434","volume":"16","author":"HJ Im","year":"1999","unstructured":"Im HJ, Kong G, Lee H . Expression of Wilms tumor gene (WT1) in children with acute leukemia. Pediatr Hematol Oncol 1999; 16: 109\u2013118.","journal-title":"Pediatr Hematol Oncol"},{"key":"BF2402988_CR32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood.V89.4.1405","volume":"89","author":"K Inoue","year":"1997","unstructured":"Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405\u20131412.","journal-title":"Blood"},{"key":"BF2402988_CR33","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V87.7.2878.bloodjournal8772878","volume":"87","author":"T Yamagami","year":"1996","unstructured":"Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M et al. Growth inhibition of human leukemic cells by WT1 (Wilms Tumor Gene) antisense oligonucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878\u20132884.","journal-title":"Blood"},{"key":"BF2402988_CR34","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V88.6.2267.bloodjournal8862267","volume":"88","author":"K Inoue","year":"1996","unstructured":"Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267\u20132278.","journal-title":"Blood"},{"key":"BF2402988_CR35","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/sj.leu.2401213","volume":"12","author":"A Gaiger","year":"1998","unstructured":"Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998; 12: 1886\u20131894.","journal-title":"Leukemia"},{"key":"BF2402988_CR36","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1182\/blood.V91.8.2961.2961_2961_2968","volume":"91","author":"L King-Underwood","year":"1998","unstructured":"King-Underwood L, Pritchard-Jones K . Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961\u20132968.","journal-title":"Blood"},{"key":"BF2402988_CR37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<176::AID-GCC14>3.0.CO;2-F","volume":"25","author":"K Miyagawa","year":"1999","unstructured":"Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K . Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer 1999; 25: 176\u2013183.","journal-title":"Genes Chromosomes Cancer"},{"key":"BF2402988_CR38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.leu.2401341","volume":"13","author":"H Tamaki","year":"2000","unstructured":"Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 2000; 13: 393\u2013399.","journal-title":"Leukemia"},{"key":"BF2402988_CR39","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.leu.2401414","volume":"13","author":"P Patmasiriwat","year":"1999","unstructured":"Patmasiriwat P, Fraizer G, Kantarjian H, Saunders GF . WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999; 13: 891\u2013900.","journal-title":"Leukemia"},{"key":"BF2402988_CR40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00062752-200103000-00001","volume":"8","author":"WF Rosse","year":"2001","unstructured":"Rosse WF . New insights into paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2001; 8: 61\u201367.","journal-title":"Curr Opin Hematol"},{"key":"BF2402988_CR41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V100.1.22","volume":"100","author":"T Shichishima","year":"2002","unstructured":"Shichishima T, Okamoto M, Ikeda K, Kaneshige T, Sugiyama H, Terasawa T et al. HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 2002; 100: 22\u201328.","journal-title":"Blood"},{"key":"BF2402988_CR42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1349-7006.1998.tb00634.x","volume":"89","author":"N Hosoya","year":"1998","unstructured":"Hosoya N, Miyagawa K, Mitani K, Yazaki Y, Hirai H . Mutation analysis of the WT1 gene in myelodysplastic syndromes. Jpn J Cancer Res 1998; 89: 821\u2013824.","journal-title":"Jpn J Cancer Res"},{"key":"BF2402988_CR43","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1046\/j.1365-2141.1999.01497.x","volume":"105","author":"N Mori","year":"1999","unstructured":"Mori N, Okada M, Motoji T, Mizoguchi H . Mutation of the WT1 gene in myelodysplastic syndrome and acute myeloid leukemia post myelodysplastic syndrome. Br J Haematol 1999; 105: 844\u2013845.","journal-title":"Br J Haematol"},{"key":"BF2402988_CR44","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/sj.leu.2401806","volume":"14","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Yamamoto R, Tanaka K, Kamada N, Miyagawa K . Mutation analysis of the WT1 gene in secondary leukemia. Leukemia 2000; 14: 1316\u20131317.","journal-title":"Leukemia"},{"key":"BF2402988_CR45","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1182\/blood.V86.12.4704.bloodjournal86124704","volume":"86","author":"G Fraizer","year":"1995","unstructured":"Fraizer G, Patmasiriwat P, Zhang X, Saunders GF . Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 1995; 86: 4704\u20134706.","journal-title":"Blood"},{"key":"BF2402988_CR46","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/oxfordjournals.annonc.a059321","volume":"6","author":"J Brieger","year":"1995","unstructured":"Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L . The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol 1995; 6: 811\u2013816.","journal-title":"Ann Oncol"},{"key":"BF2402988_CR47","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1182\/blood.V90.10.4230","volume":"90","author":"U Maurer","year":"1997","unstructured":"Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L . Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997; 90: 4230\u20134231.","journal-title":"Blood"},{"key":"BF2402988_CR48","first-page":"312","volume":"25","author":"PN Baird","year":"1997","unstructured":"Baird PN, Simmons PJ . Expression of Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25:312\u2013320.","journal-title":"Exp Hematol"},{"key":"BF2402988_CR49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<518::AID-IJC5>3.0.CO;2-0","volume":"70","author":"HD Menssen","year":"1997","unstructured":"Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E . Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 1997; 70: 518\u2013523.","journal-title":"Int J Cancer"},{"key":"BF2402988_CR50","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V96.4.1480","volume":"96","author":"A Gaiger","year":"2000","unstructured":"Gaiger A, Reese V, Disis ML, Cheever MA . Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000; 96: 1480\u20131489.","journal-title":"Blood"},{"key":"BF2402988_CR51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2141.2002.03261.x","volume":"116","author":"N Hosen","year":"2002","unstructured":"Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116: 409\u2013420.","journal-title":"Br J Haematol"},{"key":"BF2402988_CR52","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.V87.6.2171.bloodjournal8762171","volume":"87","author":"L King-Underwood","year":"1996","unstructured":"King-Underwood L, Pritchard-Jones K . Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996; 87: 2171\u20132179.","journal-title":"Blood"},{"key":"BF2402988_CR53","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/blood.V89.9.3486","volume":"89","author":"HD Menssen","year":"1997","unstructured":"Menssen HD, Renkl HJ, Entezami M, Thiel E . Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89: 3486\u20133487.","journal-title":"Blood"},{"key":"BF2402988_CR54","first-page":"945","volume":"25","author":"U Maurer","year":"1997","unstructured":"Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L . The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997; 25: 945\u2013950.","journal-title":"Exp Hematol"},{"key":"BF2402988_CR55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0145-2126(99)00037-5","volume":"23","author":"A Tsuboi","year":"1999","unstructured":"Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leukemia Res 1999; 23: 499\u2013505.","journal-title":"Leukemia Res"},{"key":"BF2402988_CR56","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2402303","volume":"15","author":"H Svedberg","year":"2001","unstructured":"Svedberg H, Richter J, Gullberg U . Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. Leukemia 2001; 15: 1914\u20131922.","journal-title":"Leukemia"},{"key":"BF2402988_CR57","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/emboj\/20.8.1897","volume":"20","author":"LW Ellisen","year":"2001","unstructured":"Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA . The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897\u20131909.","journal-title":"EMBO J"},{"key":"BF2402988_CR58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V95.1.286","volume":"95","author":"H Ohminami","year":"2000","unstructured":"Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286\u2013293.","journal-title":"Blood"},{"key":"BF2402988_CR59","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","volume":"95","author":"L Gao","year":"2000","unstructured":"Gao L, Bellantuono I, Els\u00e4sser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198\u20132203.","journal-title":"Blood"},{"key":"BF2402988_CR60","first-page":"353","volume":"26","author":"ED Zanjani","year":"1998","unstructured":"Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M . Human bone marrow CD34\u2212 cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol 1998; 26: 353\u2013360.","journal-title":"Exp Hematol"},{"key":"BF2402988_CR61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0074-7696(08)60418-0","volume":"181","author":"AL Menke","year":"1998","unstructured":"Menke AL, van der Eb AJ, Jochemsen AG . The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int Rev Cytol 1998; 181: 151\u2013212.","journal-title":"Int Rev Cytol"},{"key":"BF2402988_CR62","first-page":"1005","volume":"12","author":"EM Algar","year":"1996","unstructured":"Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ . A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12: 1005\u20131014.","journal-title":"Oncogene"},{"key":"BF2402988_CR63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-5793(97)00477-8","volume":"409","author":"Y Murata","year":"1997","unstructured":"Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T . The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett 1997; 409: 41\u201345.","journal-title":"FEBS Lett"},{"key":"BF2402988_CR64","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V91.8.2969.2969_2969_2976","volume":"91","author":"K Inoue","year":"1998","unstructured":"Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969\u20132976.","journal-title":"Blood"},{"key":"BF2402988_CR65","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0301-472X(00)00550-6","volume":"28","author":"J Greiner","year":"2000","unstructured":"Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413\u20131422.","journal-title":"Exp Hematol"},{"key":"BF2402988_CR66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.onc.1201613","volume":"16","author":"H Svedberg","year":"1998","unstructured":"Svedberg H, Chylicki K, Baldetorp B, Rauscher FJ, Gullberg U . Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene 1998; 16: 925\u2013932.","journal-title":"Oncogene"},{"key":"BF2402988_CR67","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood.V83.7.1876.1876","volume":"83","author":"M Sekiya","year":"1994","unstructured":"Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A . Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994; 83: 1876\u20131882.","journal-title":"Blood"},{"key":"BF2402988_CR68","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0301-472X(99)00038-7","volume":"27","author":"H Svedberg","year":"1999","unstructured":"Svedberg H, Chylicki K, Gullberg U . Downregulation of Wilms' tumor gene (WT1) is not a prerequisite for erythroid or megakaryocytic differentiation of the leukemic cell line K562. Exp Hematol 1999; 27: 1057\u20131062.","journal-title":"Exp Hematol"},{"key":"BF2402988_CR69","first-page":"677","volume":"5","author":"SA Phelan","year":"1994","unstructured":"Phelan SA, Lindberg C, Call KM . Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ 1994; 5: 677\u2013686.","journal-title":"Cell Growth Differ"},{"key":"BF2402988_CR70","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0145-2126(00)00064-3","volume":"24","author":"D Carrington","year":"2000","unstructured":"Carrington D, Algar E . Overexpression of murine WT1 +\/+ and \u2212\/\u2212 isoforms has no effect on chemoresistance but delays differentiation in the K562 cell line. Leukemia Res 2000; 24: 927\u2013936.","journal-title":"Leukemia Res"},{"key":"BF2402988_CR71","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood.V91.3.764","volume":"91","author":"SI Smith","year":"1998","unstructured":"Smith SI, Well D, Johnson GR, Boyd AW, Li CL . Expression of the Wilms' tumor suppressor gene, WT1, is unregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemia cells. Blood 1998; 91: 764\u2013773.","journal-title":"Blood"},{"key":"BF2402988_CR72","first-page":"808","volume":"60","author":"SI Smith","year":"2000","unstructured":"Smith SI, Down M, Boyd AW, Li CL . Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemia cell line M1 in C.B-17 scid\/scid mice. Cancer Res 2000; 60: 808\u2013814.","journal-title":"Cancer Res"},{"key":"BF2402988_CR73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-5793(97)00477-8","volume":"409","author":"Y Murata","year":"1997","unstructured":"Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T . The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett 1997; 409: 41\u201345.","journal-title":"FEBS Lett"},{"key":"BF2402988_CR74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0145-2126(97)00176-8","volume":"22","author":"T Yamagami","year":"1999","unstructured":"Yamagami T, Ogawa H, Tamaki H, Oji Y, Soma T, Oka Y et al. Suppression of Wilms' tumor gene (WT1) expression induces G2\/M arrest in leukemic cells. Leukamia Res 1999; 22: 383\u2013384.","journal-title":"Leukamia Res"},{"key":"BF2402988_CR75","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0301-472X(01)00719-6","volume":"29","author":"G Hubinger","year":"2001","unstructured":"Hubinger G, Schmid M, Linortner S, Manegold A, Bergmann L, Maurer U . Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol 2001; 29: 1226\u20131235.","journal-title":"Exp Hematol"},{"key":"BF2402988_CR76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0304-3835(98)00096-2","volume":"129","author":"M Hirose","year":"1998","unstructured":"Hirose M, Kuroda Y . p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia\/lymphoma cell lines. Cancer Lett 1998; 129: 165\u2013171.","journal-title":"Cancer Lett"},{"key":"BF2402988_CR77","first-page":"1130","volume":"111","author":"O Ringden","year":"2000","unstructured":"Ringden O, Labopin M, Gorin NC, Schmitz N, Schaefer UW, Prentice HG et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol 2000; 111: 1130\u20131137.","journal-title":"Br J Haematol"},{"key":"BF2402988_CR78","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190009087014","volume":"38","author":"DH Fowler","year":"2000","unstructured":"Fowler DH, Gress RE . Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leukemia Lymphoma 2000; 38: 221\u2013234.","journal-title":"Leukemia Lymphoma"},{"key":"BF2402988_CR79","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1073\/pnas.96.15.8639","volume":"96","author":"D Bonnet","year":"1999","unstructured":"Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR . CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 8639\u20138644.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402988_CR80","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00007890-199803150-00002","volume":"65","author":"E Simpson","year":"1998","unstructured":"Simpson E . Minor transplantation antigens. Transplantation 1998; 65: 611\u2013616.","journal-title":"Transplantation"},{"key":"BF2402988_CR81","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood.V93.7.2336","volume":"93","author":"T Mutis","year":"1999","unstructured":"Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E . Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336\u20132341.","journal-title":"Blood"},{"key":"BF2402988_CR82","unstructured":"Goulmy E . Alloimmune T cells for adoptive therapy of hematological malignancies. In: Schechter GP, Berliner N, Telen MJ, Bajus JL (eds). Hematology 2000, The American Society of Hematology Education Program Book, American Society of Hematology: Washington DC, pp 366\u2013370."},{"key":"BF2402988_CR83","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","volume":"88","author":"J Molldrem","year":"1996","unstructured":"Molldrem J, Dermine S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450\u20132457.","journal-title":"Blood"},{"key":"BF2402988_CR84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.189.2.301","volume":"189","author":"H Dolstra","year":"1999","unstructured":"Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensick E et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301\u2013308.","journal-title":"J Exp Med"},{"key":"BF2402988_CR85","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018\u20131023.","journal-title":"Nat Med"},{"key":"BF2402988_CR86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002510050018","volume":"51","author":"Y Oka","year":"2000","unstructured":"Oka Y, Elisseeva OA, Tsuboi A, Udaka K, Ogawa H, Li H et al. Human cytotoxic T-lumphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99\u2013107.","journal-title":"Immunogenetics"},{"key":"BF2402988_CR87","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.0007-1048.2001.03329.x","volume":"116","author":"T Azuma","year":"2002","unstructured":"Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M . Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002; 116: 601\u2013603.","journal-title":"Br J Haematol"},{"key":"BF2402988_CR88","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.4049\/jimmunol.164.4.1873","volume":"164","author":"Y Oka","year":"2000","unstructured":"Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000; 164: 1873\u20131880.","journal-title":"J Immunol"},{"key":"BF2402988_CR89","first-page":"16","volume":"54","author":"ML Disis","year":"1994","unstructured":"Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al. Existent T-cell and antibody immunity to HER-2\/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16\u201320.","journal-title":"Cancer Res"},{"key":"BF2402988_CR90","first-page":"1463","volume":"1","author":"R Lubin","year":"1995","unstructured":"Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP . p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995; 1: 1463\u20131469.","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"BF2402988_CR91","first-page":"761s","volume":"7","author":"A Gaiger","year":"2001","unstructured":"Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res. 2001; 7(Suppl): 761s\u2013765s.","journal-title":"Clin Cancer Res"},{"key":"BF2402988_CR92","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.V99.9.3272","volume":"99","author":"OA Elisseeva","year":"2002","unstructured":"Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272\u20133279.","journal-title":"Blood"},{"key":"BF2402988_CR93","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1073\/pnas.88.21.9618","volume":"88","author":"DA Haber","year":"1991","unstructured":"Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE . Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991; 88: 9618\u20139622.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402988_CR94","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1126\/science.2244209","volume":"30","author":"FJ Rauscher III","year":"1990","unstructured":"Rauscher III FJ, Morris JF, Tournay OE, Cook DM, Curran T . Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990; 30: 1259\u20131262.","journal-title":"Science"},{"key":"BF2402988_CR95","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1654597","volume":"253","author":"SL Madden","year":"1991","unstructured":"Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher III FJ . Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 1991; 253: 1550\u20131553.","journal-title":"Science"},{"key":"BF2402988_CR96","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1365-2141.2002.03728.x","volume":"118","author":"JP Van Dijk","year":"2002","unstructured":"Van Dijk JP, Knops GH, Van De Locht LT, Menke AL, Jansen JH, Mensink EJ et al. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol 2002; 118: 1027\u20131033.","journal-title":"Br J Haematol"},{"key":"BF2402988_CR97","first-page":"637","volume-title":"Current Opinion in Immunology","author":"ML Disis","year":"1996","unstructured":"Disis ML, Cheever MA . Oncogenic proteins as tumor antigens. In: Alt F, Marrack P (eds). Current Opinion in Immunology, Vol. 5. London U.K: Current biology Ltd., 1996, pp 637\u2013642."},{"key":"BF2402988_CR98","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1006637529995","volume":"20","author":"A Tsuboi","year":"2000","unstructured":"Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000; 20: 195\u2013202.","journal-title":"J Clin Immunol"},{"key":"BF2402988_CR99","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","volume":"94","author":"ED Kwon","year":"1997","unstructured":"Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997; 94: 8099\u20138103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402988_CR100","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1128\/IAI.69.5.3041-3047.2001","volume":"69","author":"A Tanghe","year":"2001","unstructured":"Tanghe A, D'Souza S, Rosseels V, Denis O, Ottenhoff TH, Dalemans W et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immunol 2001; 69: 3041\u20133047.","journal-title":"Infect Immunol"},{"key":"BF2402988_CR101","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1073\/pnas.071063898","volume":"98","author":"S Surman","year":"2001","unstructured":"Surman S, Lockey TD, Slobod KS, Jones B, Riberdy M, White SW et al. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci USA 2001; 98: 4587\u20134592.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402988_CR102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.292.5514.69","volume":"292","author":"RR Amara","year":"2001","unstructured":"Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine. Science 2001; 292: 69\u201374.","journal-title":"Science"},{"key":"BF2402988_CR103","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/jhep.2001.21594","volume":"33","author":"P Pancholi","year":"2001","unstructured":"Pancholi P, Lee DH, Liu Q, Tackney C, Taylor P, Perkus M et al. DNA prime\/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001; 33: 448\u2013454.","journal-title":"Hepatology"},{"key":"BF2402988_CR104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-2478(00)00244-3","volume":"74","author":"MC Bonnet","year":"2000","unstructured":"Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000; 74: 11\u201325.","journal-title":"Immunol Lett"},{"key":"BF2402988_CR105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-5699(00)01612-1","volume":"21","author":"IA Ramshaw","year":"2000","unstructured":"Ramshaw IA, Ramsay AJ . The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21: 163\u2013165.","journal-title":"Immunol Today"},{"key":"BF2402988_CR106","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.5858\/2001-125-1316-IAONVC","volume":"125","author":"MR Foster","year":"2001","unstructured":"Foster MR, Johnson JE, Olson SJ, Allred C . Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001; 125: 1316\u20131320.","journal-title":"Arch Pathol Lab Med"},{"key":"BF2402988_CR107","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.94.15.8132","volume":"94","author":"GB Silberstein","year":"1997","unstructured":"Silberstein GB, Van Horn K, Strickland P, Roberts Jr CT, Daniel CW . Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997; 94: 8132\u20138137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402988_CR108","first-page":"921","volume":"61","author":"DM Loeb","year":"2001","unstructured":"Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001; 61: 921\u2013925.","journal-title":"Cancer Res"},{"key":"BF2402988_CR109","first-page":"1167","volume":"8","author":"Y Miyoshi","year":"2002","unstructured":"Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8: 1167\u20131171.","journal-title":"Clin Cancer Res"},{"key":"BF2402988_CR110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/07357909309018871","volume":"11","author":"W Bruening","year":"1993","unstructured":"Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D et al. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993; 11: 393\u2013399.","journal-title":"Cancer Invest"},{"key":"BF2402988_CR111","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/8X4T-35B7-7529-QE7X","volume":"116","author":"NS Goldstein","year":"2001","unstructured":"Goldstein NS, Bassi D, Uzieblo A . WT1 is an integral compo-nent of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001; 116: 246\u2013252.","journal-title":"Am J Clin Pathol"},{"key":"BF2402988_CR112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijc.2910590116","volume":"59","author":"U Rodeck","year":"1994","unstructured":"Rodeck U, Bossler A, Kari C, Humphreys CW, Gyorfi T, Maurer J et al. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994; 59: 78\u201382.","journal-title":"Int J Cancer"},{"key":"BF2402988_CR113","first-page":"593","volume":"45","author":"N Nonomura","year":"1999","unstructured":"Nonomura N, Imazu T, Harada Y, Nozawa M, Ono Y, Fukui T et al. Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes. Hinyokika Kiyo 1999; 45: 593\u2013597.","journal-title":"Hinyokika Kiyo"},{"key":"BF2402988_CR114","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0140-6736(93)92619-5","volume":"341","author":"T Lion","year":"1993","unstructured":"Lion T, Henn T, Gaiger A, Kalhs P, Gadner H . Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275\u2013276.","journal-title":"Lancet"},{"key":"BF2402988_CR115","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","volume":"86","author":"A Gaiger","year":"1995","unstructured":"Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371\u20132378.","journal-title":"Blood"},{"key":"BF2402988_CR116","first-page":"1353","volume":"9","author":"T Lion","year":"1995","unstructured":"Lion T, Gaiger A, Henn T, Horth E, Haas OA, Geissler K et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia. 1995; 9: 1353\u20131360.","journal-title":"Leukemia"},{"key":"BF2402988_CR117","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.1997.15.1.26","volume":"15","author":"W Stock","year":"1997","unstructured":"Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT et al. Value of molecular monitoring during the treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 1997; 15: 26\u201336.","journal-title":"J Clin Oncol"},{"key":"BF2402988_CR118","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<741::AID-IJC22>3.0.CO;2-1","volume":"86","author":"KA Kreuzer","year":"2000","unstructured":"Kreuzer KA, Lass U, Nagel S, Ellerbrok H, Pauli G, Pawlaczyk-Peter B et al. Applicability of an absolute quantitative procedure to monitor intra-individual bcr\/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients. Int J Cancer 2000; 86: 741\u2013746.","journal-title":"Int J Cancer"},{"key":"BF2402988_CR119","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","volume":"97","author":"E Olavarria","year":"2001","unstructured":"Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560\u20131565.","journal-title":"Blood"},{"key":"BF2402988_CR120","first-page":"163","volume":"33","author":"PL Greenberg","year":"1996","unstructured":"Greenberg PL . Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol 1996; 33: 163\u2013175.","journal-title":"Semin Hematol"},{"key":"BF2402988_CR121","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2001-12-0188","volume":"100","author":"L Nilsson","year":"2002","unstructured":"Nilsson L, Astrand-Grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D et al. Involvement and functional impairment of the CD34(+)CD38(\u2212)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002; 100: 259\u2013267.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402988.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402988","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402988.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:24:20Z","timestamp":1648776260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,20]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7,1]]}},"alternative-id":["BF2402988"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402988","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,20]]}}}